Earnings call transcript: Leidos tops Q3 2026 EPS forecast but shares fall

Leidos reported Q3 adjusted EPS of $3.62, beating the $3.05 consensus by 18.7%, while revenue of $4.63 billion missed the $4.71 billion estimate by 2.3%; shares fell 6.62% in premarket trading. Free cash flow was $476 million for the quarter and $1.5 billion year to date, backlog reached $49.6 billion, and management raised full-year 2026 guidance. However, management said 2027 will not be a bottom-line growth year, citing the VBA contract transition.

Analysis

The selloff is a rational repricing of earnings quality and visibility, not just a reaction to a modest sales miss. Cost control, favorable contract adjustments and a tax benefit helped convert low organic growth into outsized EPS growth; absent repeatable volume growth, that conversion is vulnerable as cost-plus work normalizes. Cash generation is supportive, but verify how much reflects working-capital timing and whether elevated defense-capacity spending converts into production revenue and segment margin rather than stranded capacity.

The key asymmetry is the VBA recompete: the draft structure could reward incumbency and performance with greater work share, but neither award share nor economics are bounded yet. The extension into 1H27 delays the cliff; it does not resolve the 2027 earnings reset. The final RFP and award decisions are the near-term catalysts, while defense-tech ramps, energy and cyber are a 6–18 month offset—not an immediate substitute for lost Health earnings. Competitors able to absorb contract share may gain, but pricing pressure could dilute sector economics and constrain Leidos’s upside even if it retains work.

Contrarian view: the market may be discounting a severe VBA downside while giving insufficient credit to the backlog conversion and non-Health mix shift. Conversely, backlog is not revenue, and management’s long-dated growth narrative does not remove a near-term earnings trough. The thesis improves only if non-Health growth converts to durable operating profit and funded awards; it fails if defense ramps slip, capex rises without margin progression, or VBA share/pricing disappoints.

Key Decisions for Investors

• Do not chase the premarket decline as a standalone value signal. Keep LDOS neutral until the final VBA RFP clarifies vendor count, work-share criteria and pricing; reassess around the expected 2027 award decision. A material reduction in incumbent work share or adverse pricing would invalidate the downside-is-overdone thesis.
• For a tactical bullish expression, consider a small, defined-risk LDOS call spread only after the final RFP is published and the stock stabilizes; the catalyst is reduced contract uncertainty plus evidence of defense/energy backlog conversion. Risk is a further de-rating if the award process or 2027 guidance worsens; avoid sizing on management’s unquantified pipeline claims.
• Track quarterly defense revenue and segment margins against production-capacity capex, funded-backlog conversion, and Health performance. Require evidence that defense growth produces margin expansion—not merely bookings—before adding to a 6–18 month position.
• Do not annualize the EPS beat: separate recurring operating improvement from favorable EACs, tax effects and cash-flow timing in the next filing and guidance update. Repeated revenue shortfalls or weaker-than-expected funded awards would argue that the market’s growth discount is warranted.